Ocugen, Inc. 2022 Q3 Form 10-Q Summary
Business Context and Reporting Period
Ocugen is a biotechnology company developing gene and cell therapies and vaccines. The filing covers the unaudited three and nine months ended September 30, 2022, with comparisons to the same periods in 2021. The company has not generated significant revenue and operates as one segment.
Key programs include COVAXIN and the newly licensed mucosal COVID-19 vaccine candidate OCU500, the modifier gene therapy platform led by OCU400, OCU200 for retinal diseases, and NeoCart for knee cartilage repair.
Financial Metrics
| Metric | Three Months Ended September 30 | Nine Months Ended September 30 |
|---|---|---|
| Revenue | None reported | None reported |
| Research and development expense | $15.6 million, versus $6.3 million | $32.5 million, versus $28.0 million |
| General and administrative expense | $7.5 million, versus $4.5 million | $28.2 million, versus $15.5 million |
| Total operating expenses | $23.1 million, versus $10.8 million | $60.7 million, versus $43.5 million |
| Net loss | $21.9 million, or $0.10 per share | $59.4 million, or $0.28 per share |
| Operating cash flow | Not separately reported | $(43.2) million, versus $(35.1) million |
| Cash and cash equivalents | $101.6 million at September 30, 2022 | |
| Debt | $2.3 million net carrying value, principally EB-5 borrowings |
Because the company reported no revenue, gross margin and operating margin are not meaningful or clearly provided in the filing. The accumulated deficit was $191.1 million, and accounts payable and accrued expenses totaled $14.5 million at September 30, 2022.
Material Changes Versus the Prior Comparable Period
- Third-quarter research and development expense increased $9.3 million, primarily from COVAXIN clinical and CMC activities, higher employee costs, OCU200 preclinical work, and the $1.0 million initial license fee for OCU500.
- Nine-month research and development expense increased $4.5 million. Increases in COVAXIN, employee, OCU200, OCU410, and OCU500 costs were partly offset by the $15.0 million COVAXIN Canada upfront payment recorded in 2021.
- General and administrative expense increased $3.0 million in the quarter and $12.7 million for the nine months, driven by employee and stock-based compensation costs, professional and consulting fees, pre-commercialization activities, insurance, and new headquarters expenses.
- Net loss increased $11.2 million for the quarter and $15.6 million for the nine months compared with 2021.
- Cash used in operations increased to $43.2 million for the nine months from $35.1 million. Financing cash inflow decreased to $51.3 million from $120.1 million, although 2022 included approximately $49.8 million of net proceeds from a February public offering.
- Common shares outstanding increased to approximately 216.7 million at September 30, 2022, from approximately 199.4 million at December 31, 2021, primarily reflecting the February offering and equity compensation activity.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
- Management believes the $101.6 million cash balance will fund operations and capital requirements through at least one year from issuance of the financial statements and, under updated projections, into the fourth quarter of 2023. The projection excludes external COVAXIN expenditures beyond the ongoing Phase 2/3 trial.
- Management expects to continue raising capital through equity or debt offerings, the $160.0 million at-the-market facility, strategic arrangements, licensing, asset sales, and government funding. The company subsequently sold 2.1 million shares under the facility and received $3.6 million of net proceeds.
- COVAXIN’s U.S. Phase 2/3 immuno-bridging and broadening trial enrolled more than 400 participants. Top-line data were expected in early 2023. An additional adult safety trial was subject to FDA discussions and government funding.
- The company withdrew its Canadian New Drug Submission in August 2022 and was evaluating requirements for resubmission. COVAXIN retained Mexican adult emergency-use authorization, while pediatric authorization remained under discussion.
- In September 2022, Ocugen licensed OCU500 from Washington University for the United States, Europe, and Japan. The agreement includes annual fees, up to $37.0 million of regulatory and commercial milestone payments, and low-single-digit royalties on net sales.
- OCU400 dosing had been completed in two of three cohorts; dosing in the third cohort began in October 2022, with enrollment expected to be completed by year-end 2022. IND submissions for OCU410 and OCU200 were targeted for the second quarter and first quarter of 2023, respectively.
- The company withdrew a $14.3 million COVAXIN component supply commitment after deficiencies were identified in a World Health Organization inspection of Bharat Biotech. These deficiencies could affect regulatory review, manufacturing, supply, technology transfer, and commercialization.
- Two consolidated securities class actions and related shareholder derivative litigation remain pending. Ocugen believes the claims are without merit; no loss was accrued because a probable and reasonably estimable loss could not be established.
- The company remains dependent on regulatory approvals, clinical results, third-party manufacturers and suppliers, collaborators, government funding, additional financing, and market acceptance. Failure to obtain funding could require delaying, reducing, or eliminating programs or pursuing strategic alternatives.
Important Facts for Investors to Verify
- Whether the cash runway remains consistent with management’s fourth-quarter 2023 estimate after subsequent spending, financing, and program changes.
- The results and regulatory consequences of the COVAXIN Phase 2/3 trial, any adult safety trial, and the response to the WHO inspection deficiencies.
- The timing and feasibility of COVAXIN regulatory submissions or resubmissions in the United States, Canada, and Mexico.
- The company’s ability to obtain government funding for COVAXIN and OCU500 and to complete manufacturing technology transfers.
- Future equity issuance under the at-the-market facility and the resulting dilution.
- Clinical, regulatory, manufacturing, and financing milestones for OCU400, OCU410, OCU200, OCU500, and NeoCart.
- The outcome and potential financial exposure from the securities class actions and derivative litigation.